Pacira Pharma (PCRX) Misses Q1 EPS by 15c

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of ($0.19), $0.15 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $69.3 million versus the consensus estimate of $70.24 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• LVMH achieves 3% organic revenue growth in the first quarter
• Morgan Stanley (MS) earnings beat lifts stock
• UnitedHealth Group (UNH) Tops Q1 EPS by 29c, Tops on Revenue; Offers FY24 EPS Guidance